Transactions by persons discharging managerial responsibilities and persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
(‘Mediclinic’, the ‘Company’ or the ‘Group’)
12 July 2019
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 11 July 2019, Dr Ronnie Van der Merwe purchased 11 000 shares in Mediclinic International plc at
ZAR 56.90 per share. Accordingly, Dr Van der Merwe now owns a total of 51 630 Shares.
The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
1. Details of PDMR / persons closely associated with them (‘PCA’)
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic International plc
b) Initial notification / Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
a) Description of the Ordinary Shares
Identification Code GB00B8HX8Z88
b) Nature of the Purchase of shares
c) Price(s) and Price(s) Volume(s)
volume(s) ZAR 56.84 per share 1 000
ZAR 56.85 per share 2 831
ZAR 56.86 per share 1 000
ZAR 56.87 per share 3 000
ZAR 56.98 per share 2 000
ZAR 57.00 per share 1 169
Aggregated volume 11 000
Price ZAR 56.90
e) Date of the 11 July 2019
f) Place of the Johannesburg Stock Exchange
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21 outpatient clinics.
Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with
more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute
hospitals and 12 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East
operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient
beds in the United Arab Emirates.
The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 12/07/2019 01:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (‘JSE’).
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.